Keyvan Keyvanfar
YOU?
Author Swipe
View article: Optimizing CAR Costimulatory Domains Using Contrastive Learning and Optimal Transport on High-Throughput Screening Data
Optimizing CAR Costimulatory Domains Using Contrastive Learning and Optimal Transport on High-Throughput Screening Data Open
Chimeric Antigen Receptors (CARs) are engineered into immune cells to bestow specificity towards identified targets on cancer cells. CAR T cells have established themselves as therapies for B cell and plasma cell malignancies, where they i…
View article: Supplementary fig 2 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 2 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Scatter plot of the TRBV frequency as detected by next generation sequencing (NGS) and flow cytometry. Spearman rho correlation coefficient and two tail p-value are shown.
View article: Supplementary fig 2 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 2 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Scatter plot of the TRBV frequency as detected by next generation sequencing (NGS) and flow cytometry. Spearman rho correlation coefficient and two tail p-value are shown.
View article: Supplementary Tables from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary Tables from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Supplementary Tables
View article: Data from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Data from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Purpose:In chronic lymphocytic leukemia (CLL), the T-cell receptor (TCR) repertoire is skewed and tumor-derived antigens are hypothesized as drivers of oligoclonal expansion. Ibrutinib, a standard treatment for CLL, inhibits not only Bruto…
View article: Supplementary fig 4 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 4 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Expansion of T cells under different conditions. Total CD3+, CD8+, CD4+ counts at Day 0 and Day 7 of expansion in the presence of anti-CD3/CD28/CD137 beads or autologous CLL cells.
View article: Supplementary fig 1 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 1 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
T cell counts at baseline, time of ibrutinib response, and progressive disease (PD). Individual values, median and interquartile range are shown. Dashed lines indicate the lower and upper limits of the normal reference range.
View article: Supplementary fig 3 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 3 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
(A) Frequency of predominant clonotypes as detected by NGS and of the corresponding CD8+ TRBV families as measured by flow cytometry. Grey bars indicate TRBV families that did not have commercially available fluorescent-labelled antibodies…
View article: Supplementary fig 4 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 4 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Expansion of T cells under different conditions. Total CD3+, CD8+, CD4+ counts at Day 0 and Day 7 of expansion in the presence of anti-CD3/CD28/CD137 beads or autologous CLL cells.
View article: Supplementary fig 3 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 3 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
(A) Frequency of predominant clonotypes as detected by NGS and of the corresponding CD8+ TRBV families as measured by flow cytometry. Grey bars indicate TRBV families that did not have commercially available fluorescent-labelled antibodies…
View article: Supplementary fig 5 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 5 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Histogram of PD-1 expression in total CD3+, total CD8+, and the most abundant CD8+ clonotype in each patient after expansion with beads or autologous CLL cells.
View article: Data from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Data from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Purpose:In chronic lymphocytic leukemia (CLL), the T-cell receptor (TCR) repertoire is skewed and tumor-derived antigens are hypothesized as drivers of oligoclonal expansion. Ibrutinib, a standard treatment for CLL, inhibits not only Bruto…
View article: Supplementary fig 1 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 1 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
T cell counts at baseline, time of ibrutinib response, and progressive disease (PD). Individual values, median and interquartile range are shown. Dashed lines indicate the lower and upper limits of the normal reference range.
View article: Supplementary Tables from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary Tables from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Supplementary Tables
View article: Supplementary fig 5 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Supplementary fig 5 from Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Histogram of PD-1 expression in total CD3+, total CD8+, and the most abundant CD8+ clonotype in each patient after expansion with beads or autologous CLL cells.
View article: Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1
Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1 Open
Ex vivo gene therapy procedures targeting hematopoietic stem and progenitor cells (HSPCs) predominantly utilize lentivirus-based vectors for gene transfer. We provide the first pre-clinical evidence of the therapeutic utility of a foamy vi…
View article: BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL Open
Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with chronic lymphocytic leukemia (CLL). Indefinite therapy with BTKis, although effective, presents clinical challenges. Combination therapy can deepen respon…
View article: Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Open
Purpose: In chronic lymphocytic leukemia (CLL), the T-cell receptor (TCR) repertoire is skewed and tumor-derived antigens are hypothesized as drivers of oligoclonal expansion. Ibrutinib, a standard treatment for CLL, inhibits not only Brut…
View article: Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia
Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia Open
Diamond Blackfan Anemia (DBA) is a congenital macrocytic anemia associated with ribosomal protein haploinsufficiency. Ribosomal dysfunction delays globin synthesis, resulting in excess toxic free heme in erythroid progenitors, early differ…
View article: Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation
Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation Open
Background Ex vivo production of hematopoietic stem/precursor cells (HSPCs) represents a promising versatile approach for blood disorders. Methods To derive definitive HSPCs from human embryonic stem cells (ESCs), we differentiated mesoder…
View article: Additional file 13 of Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation
Additional file 13 of Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation Open
Additional file 13: Supplemental Table 1. Raw sequencing data for CD3 cells derived from CD34+ CD43+ generated from human embryonic stem cells (hESCs) and peripheral blood mononuclear cells (PBMCs).
View article: Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system
Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system Open
One of the most promising objectives of clinical hematology is to derive engraftable autologous hematopoietic stem cells (HSCs) from human induced pluripotent stem cells (iPSCs). Progress in translating iPSC technologies to the clinic reli…
View article: Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow
Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow Open
Long noncoding RNAs (lncRNAs) are regulators of cell differentiation and development. The lncRNA transcriptome in human hematopoietic stem and progenitor cells is not comprehensively defined. We investigated lncRNAs in 979 human bone marro…
View article: Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation
Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation Open
Blockade of the T-cell exhaustion marker PD-1 to re-energize the immune response is emerging as a promising cancer treatment. Relapse of hematologic malignancy after allogeneic stem cell transplantation limits the success of this approach,…
View article: A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era Open
Key Points A CD19/CD3 single-chain Fv-Fc bsAb mediated potent killing of CLL cells by autologous T cells in vitro and in vivo. bsAb-mediated cytotoxicity was enhanced by prior therapy with ibrutinib and extended to ibrutinib-resistant dise…
View article: CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation
CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation Open
Additional sex combs-like 1 (ASXL1) is a well‑known tumor suppressor gene and epigenetic modifier. ASXL1 mutations are frequent in myeloid malignances; these mutations are risk factors for the development of myelodysplasia and also appear …